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Abstract 151 
Background  152 
Stroke disproportionately affects people in low and middle-income countries (LMICs). 153 
Although improvements in stroke care and outcomes have been reported in high income 154 
countries (HICs), little is known about practice and outcomes in LMICs. We aimed to compare 155 
patterns of care available and their association with patient outcomes across countries at 156 
different economic levels. 157 
Methods  158 
We studied the patterns and impact of practice variations (treatments used and access to 159 
services) among stroke participants in the INTERSTROKE study, an international 160 
observational study that enrolled 13,447 stroke patients from 142 clinical sites in 32 countries 161 
between January 11, 2007 and August 8, 2015. We supplemented patient data with a 162 
questionnaire about healthcare and stroke service facilities at each participating hospital. Using 163 
univariate and multivariate regression analyses to account for patient case-mix and service 164 
clustering, we estimated the association between services available, treatments given, and 165 
patient outcomes (death or dependency) at one month. 166 
Findings  167 
We obtained full information for 12,342 (92%) of 13,447 INTERSTROKE patients, from 108 168 
hospitals in 28 countries; 2576 from 38 hospitals in 10 HICs and 9766 from 70 hospitals in 18 169 
LMICs. Patients in LMICs more often (P<0.0001) had severe strokes, intracerebral 170 
haemorrhage, poorer access to services, and lower use of investigations and treatments, 171 
although only differences in patient characteristics explained the poorer clinical outcomes in 172 
LMICs.  However across all countries, access to a stroke unit was associated (P<0.0001) with 173 
improved use of investigations and treatments, access to other rehabilitation services, and  174 
improved survival without severe dependency (1.29; 1.14-1.44) which was independent of 175 
patient case-mix characteristics and other measures of care. Use of acute antiplatelet therapy 176 
was associated with improved survival (1.39; 1.12-1.72) irrespective of other patient and 177 
service characteristics. 178 
Interpretation  179 
Evidence based treatments, diagnostics, and availability of stroke units were less commonly 180 
available or used in LMICs.  Access to stroke units and appropriate use of antiplatelet therapy 181 
were associated with improved recovery. Improved care and facilities in LMICs are essential 182 
to improve outcomes.   183 
Funding 184 
This analysis was supported by Chest, Heart and Stroke Scotland. INTERSTROKE was 185 
supported by range of funders.  186 
 187 
  188 
Introduction 189 
Stroke is the second commonest cause of death worldwide and one of the leading causes of 190 
disability.1-3 Although prevention strategies can reduce this burden of disease4,5 effective and 191 
affordable treatments are essential for reducing mortality and morbidity in those who have 192 
already suffered a stroke.  Aspirin4,5 , intravenous thrombolysis4,5 and mechanical 193 
thrombectomy6 for acute ischaemic stroke, and plus stroke unit care and early rehabilitation 194 
services for all stroke patients4,5  can reduce mortality and  morbidity.  195 
The PURE study7 recently demonstrated that after stroke clinical outcomes were substantially 196 
poorer in low- and middle-income countries (LMIC) than in high income countries (HICs).  It 197 
is not clear if this reflects differences in the patient population, services available, or 198 
treatments received. In many HICs, clinical practice guidelines and national strategies now 199 
recommend the establishment of stroke units in all hospitals that care for patients with acute 200 
stroke9-13. This has been linked to an increased provision of evidence-based care14-19 and 201 
improved patient outcomes17-20. However the greatest adoption of these practices has been in 202 
HICs where most clinical trials of stroke units have been carried out.  It is not known how 203 
common stroke units are in LMICs or whether they are associated with improved 204 
outcomes.4,5,8  Such information could inform the establishment of stroke units in LMICs.  205 
INTERSTROKE is an international observational stroke study conducted in 32 countries at 206 
different economic levels.21 Individuals who had had a stroke were selected using 207 
standardised criteria and were characterised in detail.  This allowed us to compare the 208 
patterns of care available, and their association with patient outcomes, across a much broader 209 
range of healthcare settings than has previously been possible.  210 
 211 
Methods 212 
INTERSTROKE is an international case-control study of risk factors for first stroke21, which 213 
enrolled 13,447 stroke patients from 142 clinical sites in 32 countries between January 11, 2007 214 
and August 8, 2015.   215 
For this analysis of practice patterns, our hypotheses were that, across all countries studied, 216 
there would be variations in access to stroke treatments and services and that, after adjusting 217 
for variations in patient case-mix, patient outcomes will be influenced by the treatments and 218 
services they can access. We proposed that outcomes would be better where; i) healthcare 219 
resources are greater, ii) guideline investigations and treatments are provided, and iii) guideline 220 
services (especially stroke units) are available at the hospital.   221 
Data collection operated at two levels; 222 
a) Individual stroke patient data included the following; demographic features (age, sex, level 223 
of education), risk factors, pre-stroke disability (using the modified Rankin Score22), 224 
comorbidity (based on the Charleston Comorbidity Index23), stroke characteristics (including 225 
haemorrhage or infarct classified with the Oxfordshire Community Stroke Project (OCSP) 226 
classification24, modified Rankin Score22 at baseline, level of consciousness at baseline) and 227 
acute management received at enrolment in the study (brain imaging, antiplatelet therapy, 228 
thrombolysis, lipid lowering therapy and blood pressure lowering therapy). 229 
b) Data collected at the level of the service; Using a short questionnaire (see Appendix), we 230 
collected information on service features at each participating hospital: i) local and national 231 
healthcare characteristics (e.g. source of health funding, items for payment), ii) hospital 232 
characteristics and resources (e.g. tertiary or secondary level hospital, departments and beds 233 
available), iii) stroke service characteristics (presence of stroke unit, stroke unit 234 
characteristics and resources), iv) additional features (other aspects of patient care such as 235 
post-discharge rehabilitation).  The survey was first circulated electronically in June 2011 236 
with a reminder sent in early 2012. If no there was no reply by early 2012, the electronic 237 
message was resubmitted via national leads. 238 
 239 
Outcomes 240 
Patient outcomes were recorded at one month follow up21 and included; death, discharge 241 
disposition after hospital (home, rehabilitation centre or nursing home), dependency using the 242 
modified Rankin score22, and length of hospital stay. Patient details were collected from the 243 
participants or from a proxy respondent21. 244 
Analysis 245 
We carried out the following analyses: 246 
1) Description of the patient characteristics and clinical practice (investigations, 247 
treatments and services provided) at  recruiting hospitals grouped by the 2011 World 248 
Bank Country Income Categories (CIC), using Chi-squared and t-tests, 249 
We carried out statistical analyses using SPSS V.23 and SAS V.9.4. using multivariate 250 
analyses to calculate case-mix adjusted outcomes (see below) and a 2-level multivariable 251 
model using random intercepts to take into account potential clustering of clinical practice by 252 
centre. We used multivariable logistic regression models to adjust for case-mix covariates 253 
that are known to influence patient outcomes25; age, sex, level of education, pre-stroke 254 
disability, number of comorbidities, stroke type and classification and initial stroke severity.  255 
No significant multi-collinearity was identified.  Adjustment was subsequently also made for 256 
country wealth (ranked by GDP) and clustering by centre. We then used binary logistic 257 
regression to identify variables that had the closest association with patient outcomes. 258 
Subgroup analyses stratified results by key patient and service characteristics. Availability of 259 
a stroke unit was clustered in regions and correlated with patient age, level of consciousness 260 
and stroke severity. Therefore we also sought to confirm our findings in a propensity-261 
matching analysis accounting for these variables. Finally we conducted exploratory 262 
sensitivity analyses of the association between patient outcomes and access to stroke units 263 
(with or without particular characteristics). These comparisons were based on;  264 
a) Stroke unit quality criteria26 in terms of whether six key features were present; (i) discrete 265 
ward, ii) multidisciplinary care, iii) staff specialist interest in stroke, iv) programmes of staff 266 
education and v) patient management protocols and vi) information for patients and families,  267 
b) Staffing levels that meet basic benchmark levels for nursing, medical and therapy staff26, 268 
c) Stroke unit capacity (ability to manage >50% of the stroke patients in the hospital), and  269 
d) Access to post-discharge rehabilitation.  270 
Ethics 271 
The study was approved by the ethics committees in all participating centres.21 Participants, 272 
or their proxy, provided written informed consent. None of the authors reported major 273 
conflicts of interest. 274 
 275 
Role of the funding source 276 
The current analysis was supported by a grant from Chest, Heart and Stroke Scotland. The 277 
main INTERSTROKE study was supported by several funders (see Appendix). None of the 278 
funders had a role in the study design, data collection, data analysis, data interpretation, or 279 
writing of the report. The corresponding author had full access to all the data and final 280 
responsibility for the decision to submit for publication.   281 
  282 
Results 283 
Between January 11, 2007 and August 8, 2015, the INTERSTROKE study21 enrolled 13,447 284 
acute stroke patients from 142 centres; 34 centres (1105 participants) did not provide 285 
information on the service survey. We therefore had complete individual patient data and 286 
service information from 12,342 participants from 108 hospitals in 28 countries covering 287 
Western Europe, East and Central Europe, the Middle East, Africa, South Asia, China, South 288 
East Asia, Latin America, North America and Australia.  289 
Table 1 outlines the characteristics of patients, investigations and treatments provided and 290 
services available. These are categorised by the 2011 World Bank Country Income Category. 291 
A total of 38 hospitals (2576 participants) were in HICs (Australia, Canada, Croatia, 292 
Denmark, Germany, Ireland, Poland, Sweden, United Arab Emirates, UK) and 70 hospitals 293 
(9766 participants) in LMICs. The latter consisted of 50 hospitals (5859 participants) in 294 
upper-middle income countries (Argentina, Brazil, Chile, China, Columbia, Ecuador, 295 
Malaysia, Peru, Russia, South Africa, Turkey), 17 hospitals (3361 participants) in lower-296 
middle income countries (India, Nigeria, Pakistan, Philippines, Sudan), and 3 hospitals (546 297 
participants) in low income countries (Mozambique, Uganda). LMIC hospitals (Table 1) 298 
recruited patients who were on average younger, less well educated, had fewer comorbidities, 299 
more severe strokes and more intracerebral haemorrhage (all P<0.0001).   Although CT 300 
scanning was mandated for all INTERSTROKE patients, those from HICs were more likely 301 
to get imaging done on the day of admission. Other investigations were also more readily 302 
available (Table 1). HIC patients were more likely to receive antiplatelet therapy, intravenous 303 
thrombolysis or a carotid intervention following an ischaemic stroke, but any variations in BP 304 
lowering treatments and lipid lowering therapy were not clearly linked to World Bank CIC. 305 
Data reporting was almost complete (12266; 99.4%) for all reported variables with the 306 
exception of thrombolysis and carotid interventions for which non-reporting was assumed to 307 
indicate that the treatment was not given. 308 
 309 
Table 1 also summarises the services available in each site categorised by World Bank CIC.  310 
A total of 6055 patients (49%) were admitted to hospitals reporting that they had some form 311 
of stroke unit available; (95% of centres and 92% of patients in HIC; 30% of centres and 38% 312 
of patients in LMICs). However there was no clear gradient by World Bank CIC with fewest 313 
stroke units being available in upper-middle income countries. When present, stroke units in 314 
LMICs were less likely to meet all of the six key quality characteristics26 or to report having 315 
sufficient capacity to accommodate most hospitalised stroke patients (Table 1).  This was 316 
corroborated by information that, for the same number of admissions (a median of 50 stroke 317 
patient admissions per month), HIC stroke units reported having a median of 18 beds 318 
available compared with 8 beds in LMIC units.  319 
Stroke patients from wealthier countries had better outcomes at one month. When grouped as 320 
HICs versus LMICs, the number (%) surviving and surviving without major dependency 321 
(mRS 0-3) were 2501 (98%) and 2308 (90%) respectively in HICs compared with 8580 322 
(88%) and 7536 (78%) in LMICs. This was confirmed when outcomes were regressed against 323 
country wealth; ranked from lowest to highest country GDP (Table 2).  Differences in patient 324 
characteristics appeared to explain much, but not all, of the variation by country wealth. After 325 
adjusting for baseline patient case-mix variables (age, sex, education, pre-stroke disability, 326 
stroke type, number of comorbidities, level of consciousness, and modified Rankin score at 327 
baseline) the relationship between country income and recovery was reduced but not 328 
abolished (Table 2).   There was no further attenuation of the relationship after including 329 
common medications given (antiplatelet, lipid lowering and BP lowering therapy plus 330 
thrombolysis), and access to services (medical stroke specialist, stroke unit and rehabilitation 331 
post-discharge). These results indicate that the incrementally better patient outcomes 332 
observed in wealthier countries were partly explained by patient case-mix.  333 
We then explored the relationships between treatments given, services available and patient 334 
outcomes across all World Bank CIC settings (Table 3).  For these analyses we included all 335 
treatments and services that were less common in LMIC centres (Table 1).  We did not 336 
include carotid interventions as this applied to only 97 patients overall.  After adjustment for 337 
patient case-mix and country wealth (GDP ranking), the appropriate provision of antiplatelet 338 
therapy (prescribed for those with cerebral infarction), and the availability of stroke unit care 339 
and post-discharge rehabilitation were each associated with a greater chance of survival 340 
without severe dependency (Table 3). The appropriate provision of antiplatelet therapy, and 341 
availability of stroke unit care and post-discharge rehabilitation were also associated with a 342 
higher odds of survival at one month (Table 3). When the analysis also took into account 343 
clustering by centre (Table 3), the availability of stroke unit care and post-discharge 344 
rehabilitation were each associated with a greater chance of survival without severe 345 
dependency (Table 3). The appropriate provision of antiplatelet therapy, and availability of 346 
post-discharge rehabilitation were associated with a higher odds of survival at one month 347 
when taking into account clustering by centre.  348 
Using a forward binary logistic regression, including all variables listed in Table 3, we found 349 
that survival without severe dependency (mRS 0-3) was greater with access to stroke unit 350 
care and appropriate antiplatelet therapy. Significant covariates were pre-stroke disability 351 
plus the five patient variables (age, comorbidities, baseline mRS, level of consciousness and 352 
stroke classification).  Survival at one month was best explained by appropriate antiplatelet 353 
therapy, access to stroke unit care, and access to post-discharge rehabilitation. Significant 354 
covariates were country GDP ranking, patient education and the five patient variables above.   355 
Table 4 highlights the univariate and multivariate analyses exploring the association of access 356 
to a stroke unit with the provision of other stroke treatments and with patient outcomes. 357 
Admission to a hospital with a stroke unit was associated with increased odds of receiving all 358 
the other process measures plus an increased odds of survival and survival without severe 359 
dependency. However after adjusting for clustering by centre, access to a stroke unit was only 360 
associated with increased access to CT scanning and post-discharge rehabilitation and with  361 
survival without severe dependency (1.29; 1.14-1.44).  362 
As stroke unit availability was unevenly distributed between regions we used a matched 363 
propensity analysis that excluded the five regions where availability was either universal 364 
(Western Europe, Eastern Europe, North America, Australia) or absent (Middle East). 365 
Variables that were related to patient outcomes and also closely associated with stroke unit 366 
availability were patient age and stroke severity. Therefore we compared two groups of 3,466 367 
stroke participants with or without access to a stroke unit who were matched on; age (mean of 368 
60 versus 60 years); reduced level of consciousness (45% versus 45%); baseline modified 369 
Rankin Scale, (mean of 3.40 versus 3.40).  Admission to a hospital with a stroke unit was 370 
again associated with increased odds of survival (1.15; 1.01-1.31) and of survival without 371 
major disability (1.30; 1.17-1.44).   372 
 373 
In view of the imbalance between HIC and LMIC in the numbers of patients with 374 
intracerebral haemorrhage, we repeated the analyses with the exclusion of intracerebral 375 
haemorrhages (supplemental Tables 1-2). On multivariate analyses patients with ischaemic 376 
stroke had an increased odds of survival without severe dependency (1.42; 1.23-1.64; 377 
p<0.0001) if admitted to a hospital with a stroke unit. Results were directionally consistent 378 
but non-significant for survival (1.15; 0.96-1.39; p=0.14). 379 
Further subgroup analyses found a consistent association of access to stroke unit services 380 
with patient outcomes across a range of patient and service subgroups (Figure 1). The 381 
association of improved outcomes with antiplatelet drug use was seen across all subgroups 382 
(Figure 2) except for stroke type where no benefit was seen for the very small number of 383 
haemorrhage patients treated with aspirin. 384 
 385 
Finally in sensitivity analyses we repeated the analysis in Table 4 for the outcome of survival 386 
without severe dependency (mRS 0-3) but compared stroke units with and without specific 387 
quality characteristics (as described in Table 1). The association with improved outcomes 388 
was greater in the presence (compared to absence) of quality features; the stroke unit was 389 
described as having the six key characteristics (1.32; 1.11-1.56); stroke unit staffing met basic 390 
benchmark levels (1.34; 1.11-1.62); and the stroke unit had the capacity to house at least 50% 391 
of stroke patient admissions (1.20; 1.00-1.45). The availability of post-discharge 392 
rehabilitation was not associated with additional benefit in this analysis (1.08; 0.67-1.33). 393 
Discussion 394 
We had anticipated that INTERSTROKE patients enrolled in LMIC hospitals would have 395 
poorer access to investigations, treatments and services than those from HIC hospitals. 396 
However, LMIC patients also had poorer clinical outcomes (survival 88% compared with 397 
98% in HICs; survival without severe disability 78% versus 90%) which could only be partly 398 
explained by the inclusion of more severe stroke patients. Across all countries studied, the 399 
practice variables most consistently associated with improved patient outcomes were access 400 
to stroke unit care and post-discharge rehabilitation plus receiving appropriate antiplatelet 401 
therapy. This may reflect more limited access to state or insurance funded healthcare 402 
services. 403 
The poorer stroke prognosis in LMICs has been described previously.2,3,7 We have confirmed 404 
that stroke in poorer countries appears to be either a more severe disease (more intracerebral 405 
haemorrhage) and/or has different referral patterns (patients admitted to hospital more likely 406 
to have severe stroke). The potential role of stroke units and antiplatelet therapy in LMIC 407 
settings has not been described before but is potentially complex. Access to drugs or services 408 
could not explain differences between patient outcomes in wealthy versus less wealthy 409 
countries but they did appear to explain associations across all countries. This may reflect the 410 
observation that access to a stroke unit varied greatly within as well as between wealth 411 
categories (World Bank CICs). 412 
Several observational studies16,18,20,28 have reported on the association of appropriate 413 
antiplatelet therapy (early use in acute cerebral ischaemia) with improved survival and 414 
reduced disability. Also a recent meta-analysis of aspirin trials29 confirms an important short 415 
term benefit of aspirin therapy to prevent recurrent cerebral ischaemia. However, these 416 
studies have almost all been in higher income settings28.  Earlier access to brain imaging may 417 
serve to facilitate earlier antiplatelet use. 418 
In the INTERSTROKE study, the apparent benefit of stroke units is comparable to that 419 
reported in RCTs4 and appears to be due to a combination of an “intrinsic” stroke unit effect 420 
as well as stroke unit patients having better access to antiplatelet therapy, risk factor 421 
modification, and post-discharge rehabilitation. The apparent benefits were seen across a 422 
range of stroke patient groups and tended to be greater if the stroke unit was reported to be 423 
well staffed, to meet recognised service standards, and to have sufficient capacity to provide 424 
care for most stroke patients admitted to hospital.  Our findings suggest that, stroke units can 425 
have a similar benefit in LMICs as has been observed in HICs.   426 
At present few hospitals in LMICs have stroke units. Even in our study, which is likely to 427 
have included a higher proportion of better-resourced tertiary care centres (with better access 428 
to imaging and drug therapies) than in average LMIC hospitals, only 38% had stroke units. 429 
Our study suggests that establishment of simple stroke units could enhance the level and 430 
organisation of care and improve stroke outcomes in LMICs. The World Health Organisation 431 
has targeted a 25% reduction in premature mortality from cardiovascular disease globally by 432 
2025. This is unlikely to be achieved by risk factor reduction alone but also requires 433 
investment in medical treatments and organisation of better systems of care. Investment in 434 
specialised stroke units is likely to be cost effective and should be a priority worldwide. 435 
Limitations of this study include the observational design which cannot completely exclude 436 
the possibility of residual confounding. We carried out a large number of analyses which 437 
raises the possibility of chance findings. However, use of the 99% confidence threshold 438 
would not alter our main conclusions. Service features were described at the level of the 439 
hospital so we cannot be certain which specific patients were actually admitted to a stroke 440 
unit.  Although this introduces some uncertainty it also reduces any potential bias resulting 441 
from selective admission of better prognosis patients within a hospital to the stroke unit; it is 442 
testing the impact of the stroke unit on all patients at that hospital. Interestingly the sensitivity 443 
analyses suggest improved outcomes where stroke units had greater capacity to accept most 444 
stroke patients. As only a proportion of patients were enrolled in INTERSTROKE it is 445 
possible (but unlikely) that stroke unit sites enrolled patients with a better prognosis. An 446 
additional challenge was that service characteristics tended to cluster together in hospitals, 447 
countries and regions making it difficult to separate the impact of different aspects of service 448 
delivery.  In particular, the availability of post-discharge rehabilitation services was closely 449 
related to stroke units.  Finally, several regions had no variation in the provision of stroke 450 
units, although exclusion of these regions from the analysis did not alter our conclusions.   451 
The strengths of our study are that we collected standardised information from over 12,000 452 
well-characterised acute stroke patients including an independent assessment of outcome at 453 
one month. We recruited from a large number of hospitals in diverse settings with variations 454 
in care. This was facilitated by national co-ordinators and investigators who were trained in 455 
collecting data in a standardised manner. The study investigators had a research interest in 456 
stroke epidemiology, but there was not usually a special interest in service delivery.  457 
Although we recognise that the hospitals participating in INTERSTROKE are likely to have 458 
had a higher level of resources and support than is typical of poorer resourced areas, we know 459 
of no other study that has obtained such a broad range and quality of data using such 460 
standardised and prospective methods. If the centres participating in INTERSTROKE were 461 
better equipped than the average centres in each country ( especially in LMICs), the gaps 462 
between HIC and LMIC in  facilities , organized care , treatments and outcomes for stroke 463 
patients may be even greater than what we report. 464 
Several previous studies have explored the potential impact of indicators of service quality in 465 
routine hospital settings,27,28  however, almost all have been carried out in HIC settings. The 466 
most recent review of LMICs8 could only identify limited observational information that 467 
could not adjust for confounders. Individual case studies in India, Thailand, South Africa and 468 
Mauritania8 suggested that stroke unit care could have a beneficial impact in those settings. 469 
Only two studies have explored the impact of antiplatelet agents in LMICs and their results 470 
were inconclusive28. 471 
We believe that this analysis supports the widespread provision of appropriate early 472 
antiplatelet therapy and stroke unit care within hospitals in LMIC settings.  It also indicates 473 
that a certain basic standard of care and supporting resources are likely to be needed to fully 474 
realise these benefits. These include adequate staffing and the capacity to accept the majority 475 
of stroke patients.  Further research needs to develop and test methods of effectively 476 
implementing lower-cost, regionally appropriate models of stroke unit care. 477 
 478 
Research in context 
Evidence before this study 
We searched Medline, EMBASE and PubMed from January 1, 2000 to May 24, 2017, for 
large stroke register studies using Medical Subject Headings including stroke OR cerebral 
hemorrhage OR cerebral infarction AND quality indicator OR performance indicator OR 
quality improvement OR quality of care OR quality of health care OR registry OR register 
OR audit AND outcome OR mortality OR case fatality OR survival OR disability OR 
function OR recovery OR discharge OR discharge destination OR return home OR 
complications.. We identified 20 studies but none had been done in low or middle-income 
country settings. 
Added value of this study 
This is the first large study to use standardised, prospective data collection across a range of 
CIC levels in over 12,000 carefully characterised acute stroke patients from 108 hospitals in 
28 countries. We have found that evidence-based treatments, diagnostics, and availability of 
stroke units were less common in LMICs.  Access to stroke units and appropriate antiplatelet 
therapy were consistently associated with improved recovery.  
 
Implications of all the available evidence 
This analysis supports the widespread provision of appropriate early antiplatelet therapy 
and stroke unit care within hospitals in LMIC settings.  A certain basic standard of care and 
supporting resources are likely to be needed to fully achieve these benefits. Further 
research needs to develop and test methods of effectively implementing lower-cost, 
regionally appropriate models of stroke unit care. 
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 Table 1 Patient and practice characteristics categorised by World Bank country income category (CIC) 
 
Category Detail World Bank Income CIC Significance 
High Upper-middle Lower-middle or 
low 
Participant characteristics Number 2576 5859 3907 N/A 
Countries Number 10 11 7 " 
Centres Number 38 50 20 " 
Patient characteristics      
Age 
Sex 
Education 
Mean (SD) 65·8 (13·8) 62·7 (13·3) 59·1 (13·5) P<0·0001 
n (%) male 1543 (60%) 3331 (57%) 2359 (60%) P=0·001 
None/primary 449 (17%) 3832 (66%) 2234 (58%) P<0·0001 
High school, trade college or university 2127 (83%) 2025 (34%) 1673 (42%)  
Charleston Index Comorbidity None 730 (28%) 1886 (32%) 1430 (37%) P<0·0001 
One or more 1845 (72%) 3972 (68%) 2477 (63%)  
Independent Pre-stroke Modified Rankin Scale 0-2 2481 (96%) 5794 (99%) 3871 (99%) P=0·001 
Stroke classification Intracerebral haemorrhage 
Infarct – Total Anterior Circulation  
258 (10%) 
111 (4%) 
1666 (28%) 
280 (5%) 
1275 (32%) 
208 (5%) 
P<0·0001 
Infarct – Partial Anterior Circulation 1022 (40%) 1927 (33%) 1319 (34%)  
Infarct – Posterior Circulation 406 (16%) 549 (9%) 311 (8%)  
Infarct – Lacunar 706 (27%) 1149 (20%) 574 (15%)  
Unclassified 70 (3%) 288 (5%) 219 (6%)  
Level of consciousness Reduced 189 (7%) 1640 (28%) 2116 (54%) P<0·0001 
Baseline dependency  
(modified Rankin score; mRS) 
Mild (mRS 0-2) 
Moderate (mRS 3) 
Severe (mRS 4) 
Very severe (mRS 5) 
1605 (62%) 
472 (18%) 
373 (15%) 
126 (5%) 
2180 (37%) 
1636 (28%) 
1391 (24%) 
651 (11%) 
894 (23%) 
994 (25%) 
1076 (28%) 
942 (24%) 
P<0·0001 
Length of stay in hospital Mean (days) 9 16 6 P<0·0001 
Investigations performed in hospital     
Investigations CT scan on day 1 
MRI scanning 
2460 (96%) 
503 (20%) 
5567 (95%) 
611 (10%) 
3455 (89%) 
43 (1%) 
P<0·0001 
P<0·0001 
 Holter monitoring 608 (24%) 94 (2%) 2 (1%) P<0·0001 
 Carotid Doppler 1653 (64%) 1175 (20%) 76 (2%) P<0·0001 
Treatments given in hospital      
Treatments Antiplatelet drugs for cerebral infarct 2344 (91%) 5121 (87%) 3116 (85%) P<0·0001 
 Lipid lowering for cerebral infarct 1865 (72%) 4222 (72%) 3140 (80%) P<0·0001 
 Thrombolysis (iv) for infarct (a) 463 (20%) 168 (4%) 73 (3%) P<0·0001 
Carotid intervention for infarct (a, b) 79 (3%) 16 (<1%) 2 (<1%) P<0·0001 
BP lowering for any stroke 1818 (71%) 3881 (66%) 2972 (76%) P<0·0001 
Services available at centre      
Hospital type Tertiary (versus secondary or local) 1839 (72%) 3090 (53%) 2690 (69%) P<0·0001 * 
Medical stroke specialist availability Any stroke specialist available 2397 (96%) 5155 (88%) 2410 (62%) P<0·0001 * 
Capacity to look after >50% of patients 2259 (90%) 4805 (82%) 1512 (39%) P<0·0001 ** 
Stroke unit availability Any stroke unit available 2370 (92%) 1323 (23%) 2362 (61%) P<0·0001 ** 
 Capacity to look after >50% of patients 2236 (89%) 1297 (22%) 1334 (34%) P<0·0001 ** 
 Unit meets all key characteristics (c) 1767 (71%) 1088 (19%) 783 (20%) P<0·0001 ** 
 Unit meets all staffing benchmarks (d) 475 (18%) 408 (7%) 723 (18%) P<0·0001 ** 
Post-discharge rehabilitation  Any service available 2357 (92%) 2170 (37%) 1214 (31%) P<0·0001 ** 
Family training in rehabilitation  Any education of family reported 2169 (84%) 4418 (75%) 2509 (64%) P<0·0001 * 
 
The table summarises regional variations in the patient characteristics, services investigations and treatments available for stroke participants 
recruited to INTERSTROKE and grouped according to World Bank Income Category. Note all patients recruited were expected to have brain 
imaging (usually CT scan) and a 12 lead ECG.  
Key: mRS = modified Rankin Scale; CT = Computerised Tomography; MRI = Magnetic Resonance Imaging; BP=blood pressure. 
a) Substantial missing data which were assumed to indicate non-treatment. 
b) Usually carotid endarterectomy (a small number had carotid stenting).  
c) The stroke unit characteristics included26; discrete ward, staff who specialise in stroke, regular multidisciplinary team (MDT) meetings, 
protocols for care in place, programmes of education and training for staff, information provided for patients and carers. 
d) Basic stroke unit staffing was benchmarked 26 at a staff complement (to cover all shifts) of 1·0 whole time equivalent of nursing staff per bed, 
0·1 whole time equivalent of therapist, and 0·1 whole time equivalent of doctor.  
All comparisons are at the level of the patient.  As the services available were clustered at centres we also compared at the level of the centres: * Proportions 
differ at P<0·01; ** at P<0·0001. 
 
 
Table 2 Patient outcomes at one month by country wealth: univariate and multivariate analyses  
 
Outcome category at one month Odds of a better outcome for each increase in ranking of country GDP 
Univariate analysis 
(OR and 95% CI) 
Multivariate analysisi 
(OR and 95% CI) 
Multivariate analysisii 
(OR and 95% CI) 
Multivariate analysisiii 
(OR and 95% CI) 
Multivariate analysisiv 
Clustered by centre 
(OR and 95%CI) 
Full recovery (mRS 0-1) vs worse  1·05 (1·04-1·05) 
P<0·0001 
1·01 (0·99-1·01) 
P=0·72 
1·00 (0·99-1·01) 
P=0·91 
1·01 (0·99-1·00) 
P=0·07 
1·01 (0·99-1·00) 
P=0·08 
Independent (mRS 0-2) vs worse  1·05 (1·05-1·06) 
P<0·0001 
1·00 (0·99-1·01) 
P=0.95 
1·00 (0·99-1·01) 
P=0·99 
1·00 (0·99-1·01) 
P=0·99 
1·01 (0·99-1·01) 
P=0·43 
No major dependency (mRS 0-3) vs worse  1·06 (1·05-1·08) 
P<0·0001 
1·00 (0·99-1·01) 
P=0·59 
1·00 (0·99-1·01) 
P=0·47 
0·99 (0·99-1·02) 
P=0·07 
1·00 (0·99-1·01) 
P=0·70 
Without very severe dependency (mRS 0-4) 
vs worse  
1·10 (1·09-1·10) 
P<0·0001 
1·02 (1·01-1·04) 
P<0·0001 
1·03 (1·02-1·04) 
P<0·0001 
1·02 (1·01-1·03) 
P=0·0005 
1·03 (1·02-1·04) 
P<0·0001 
Alive (mRS 0-5) vs dead  1·12 (1·11-1·14) 
P<0·0001 
1·05 (1·04-1·06) 
P<0·0001 
1·05 (1·04-1·06) 
P<0·0001 
1·05 (1·03-1·06) 
P<0·0001 
1·06 (1·04-1·07) 
P<0·0001 
 
 
Data are Odds Ratio (95% CI); p value. Exploration of the association between country wealth and odds of patients having a better outcome (graded by the modified 
Rankin Scale; mRS) and the gross domestic product (GDP) ranked from lowest to highest income. The univariate analysis includes only country GDP ranked from the 
highest to lowest of the 28 included countries. i) Outcomes adjusted for country GDP ranking plus participant age, sex, education, pre-stroke 
disability, stroke type (haemorrhage or Oxfordshire Community Stroke Project category of infarct), number of comorbidities (Charleston comorbidity index), level of 
consciousness, and modified Rankin score at baseline (always recorded within 5 days of stroke onset). ii) Outcomes adjusted for all of the above plus common drugs given 
(antiplatelet, lipid-lowering, blood pressure-lowering treatment, and thrombolysis). iii) Outcomes adjusted for all of the above plus accounting for services available (medical 
stroke specialist, stroke unit, and rehabilitation post discharge). iv) Outcomes adjusted for those in ‡ plus clustering by centre. 
  
  
Table 3 Association of treatments available with patient outcomes at one month: univariate and multivariate analyses  
 
Outcome at one month Treatment provided or 
service available at the 
recruiting centre 
Univariate analysis 
Odds Ratio (95% CI) 
Multivariate analysis (i) 
Odds Ratio (95% CI) 
Multivariate analysis (ii) 
Odds Ratio (95% CI) 
Multivariate analysis (iii) 
Odds ratio (95%CI) 
Alive without severe 
dependency (mRS 0-3) 
Antiplatelet therapy for infarct  1·84 (1·61-2·10) 
P<0·0001 
1·28 (1·08-1·51) 
P=0·0050 
1·29 (1·09-1·53) 
P=0·0030 
1·12 (0·95-1·34) 
P=0·19 
 Thrombolysis for infarct  1·13 (0·91-1·41) 
P=0·28 
1·09 (0·83-1·43) 
P=0·54 
1·06 (0·80-1·39) 
P=0·69 
0·90 (0·68-1·18) 
P=0·44 
 Medical stroke specialist 
available * 
1·79 (1·61-1·98) 
P<0·0001 
1·04 (0·91-1·18) 
P=0·61 
0·97 (0·82-1·14) 
P=0·69 
0·91 (0·77-1·08) 
P=0·93 
 Stroke unit available * 1·25 (1·14-1·36) 
P<0·0001 
1·42 (1·27-1·59) 
P<0·0001 
1·42 (1·27-1·60) 
P<0·0001 
1·29 (1·14-1·44) 
P<0·0001 
 Post-discharge rehabilitation 
available * 
1·55 (1·43-1·70) 
P<0·0001 
1·20 (1·06-1·35) 
P=0·0030 
1·37 (1·20-1·57) 
P<0·0001 
1·18 (1·03-1·35) 
P=0·0210 
Alive (mRS 0-5) Antiplatelet therapy for infarct 2·47 (2·07-2·96) 
P<0·0001 
1·65 (1·34-2·03) 
P<0·0001 
1·62 (1·32-1·99) 
P<0·0001 
1·39 (1·12-1·72) 
P=0·0030 
 Thrombolysis for infarct  1·67 (1·15-2·43) 
P=0·0070 
1·43 (0·94-2·17) 
P=0·09 
1·10 (0·72-1·69) 
P=0·66 
0·85 (0·55-1·31) 
P=0·46 
 Medical stroke specialist 
available * 
1·62 (1·32-2·00) 
P<0·0001 
1·22 (0·97-1·54) 
P=0·09 
1·26 (0·99-1·59) 
P=0·05 
1·20 (0·94-1·52) 
P=0·14 
 Stroke unit available * 1·23 (1·09-1·39) 
P=0·0010 
1·17 (1·01-1·34) 
P=0·0340 
1·18 (1·03-1·36) 
P=0·0200 
1·00 (0·86-1·16) 
P=0·99 
 Post-discharge rehabilitation 
available * 
3·79 (3·28-4·38) 
P<0·0001 
2·26 (1·91-2·66) 
P<0·0001 
1·90 (1·58-2·28) 
P<0·0001 
1·54 (1·28-1·85) 
P>0·0001 
 
Data are Odds Ratios (95% CI); p value. The multivariate analysis used multivariate regression to show case-mix adjusted outcomes. mRS=modified Rankin 
Scale. i) Outcomes adjusted for participant age, sex, education, pre-stroke disability, stroke type (haemorrhage or Oxfordshire Community Stroke Project 
category of infarct), number of comorbidities (Charleston comorbidity index), level of consciousness, and modified Rankin score at baseline (always 
recorded within 5 days of stroke onset). ii) Outcomes adjusted for all of the above plus country income (GDP ranking). iii) Outcomes adjusted for all those in 
iv) plus centre. §Service available at the recruiting centre but not necessarily received by every patient. 
  
Table 4 Association of access to stroke unit care with processes of care and patient outcomes at one month: univariate and multivariate analyses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table shows the number (percent) of patients in both service groups in each category of process measure (care received up to one month) and outcome measure (degree of 
recovery at one month post-stroke). Univariate analyses show the unadjusted odds ratio (OR) and 95% confidence interval (CI) for the association between access to stroke 
unit care and a better clinical outcome. The multivariate analysis used multivariate regression to show case-mix adjusted outcomes that were adjusted for; i) participant age, 
sex, education, pre-stroke disability, stroke type (haemorrhage or Oxfordshire community stroke project category of infarct), number of comorbidities (Charleston 
comorbidity index); level of consciousness, and modified Rankin score at baseline (always recorded within 5 days of stroke onset), plus country income (GDP ranking), ii) all 
of ii) plus centre. 
  Key: BP=blood pressure; mRS = modified Rankin Scale.  
 
 
 
 
Outcome category at one month Stroke unit available Association with stroke unit availability 
Yes No Univariate analysis 
OR (95% CI) 
Multivariate analysisi 
OR (95% CI) 
Multivariate analysisii 
OR (95% CI) 
Process measures      
CT scan conducted on day of admission 5727 
(95%) 
5754 
(92%) 
1·69 (1·45-1·95) 
P<0·0001 
1·66 (1·43-1·94) 
P<0·0001 
1·35 (1·10-1·66) 
P=0·0040 
Antiplatelet for infarct  4148 
(86%) 
3554 
(80%) 
1·49 (1·31-1·63) 
P<0·0001 
1·40 (1·24-1·58) 
P<0·0001 
1·16 (0·99-1·34) 
P=0·06 
Lipid lowering for infarct  3366 
(70%) 
2772 
(63%) 
1·35 (1·23-1·47) 
P<0·0001 
1·33 (1·21-1·47) 
P<0·0001 
1·17 (0·76-1·81) 
P=0·48 
Thrombolysis for infarct  580 
(12%) 
123 
(3%) 
4·74 (3·88-5·78) 
P<0·0001 
3·65 (2·96-4·50) 
P<0·0001 
Insufficient data 
BP  lowering therapy given for any stroke 4357 
(72%) 
4313 
(69%) 
1·17 (1·09-1·27) 
P<0·0001 
1·29 (1·18-1·41) 
P<0·0001 
0·93 (0·73-1·17) 
P=0·52 
Post-discharge rehabilitation provided  4564 
(75%) 
1198 
(19%) 
13·0 (11·9-14·2) 
P<0·0001 
18·2 (16·4-20·3) 
P<0·0001 
86·7 (66·4-1·13) 
P<0·0001 
Clinical outcomes at one month      
Alive without severe dependency (mRS 0-3)  4936 
(82%) 
4907 
(79%) 
1·25 (1·14-1·36) 
P<0·0001 
1·41 (1·26-1·58) 
P<0·0001 
1·29 (1·14-1·44) 
P<0·0001 
Alive (mRS 0-5)  5492 
(91%) 
5588 
(89%) 
1·23 (1·09-1·39) 
P=0·0010 
1·30 (1·12-1·49) 
P<0·0001 
1·00 (0·86-1·16) 
P=0·99 
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